Everything below concerns circadian rhythm. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
=== Modern attempts at Carbon 14 dating === Various attempts at radio-carbon analysis were made over the years, with various degrees of success, but with the main effect of pushing back the dates of the first caves to circa 300 CE, and challenging the German classification according to styles and colors schemes. In 1979, a Chinese institute (文物保护科学技术研究所, Wenwu baohu kexue jishu yanjiusuo) carbon-tested caves 63, 47, 13.
In plants, ATP synthase is also present in chloroplasts (CF1FO-ATP synthase). The enzyme is integrated into thylakoid membrane; the CF1-part sticks into stroma, where dark reactions of photosynthesis (also called the light-independent reactions or the Calvin cycle) and ATP synthesis take place. The overall structure and the catalytic mechanism of the chloroplast ATP synthase are almost the same as those of the bacterial enzyme. However, in chloroplasts, the proton motive force is generated not by respiratory electron transport chain but by primary photosynthetic proteins. The synthase has a 40-aa insert in the gamma-subunit to inhibit wasteful activity when dark. CF1FO-ATP synthase is less efficient to its mitochondrial counterpart and exchanges 4—4.67 protons per ATP.
It was hoped that ANGPTL8 or its homolog in humans may provide an effective treatment for type 2 diabetes and perhaps even type I diabetes. Unfortunately, since new data have greatly called into question the ability of ANGPTL8 to increase beta-cell replication, its potential use as a therapy for type 2 diabetes is limited. Inhibition of ANGPTL8 represents a possible therapeutic strategy for hypertriglyceridemia. In a clinical trial, a human ANGPTL3/8 monoclonal antibody reduced the concentration of triglycerides (-70%), and low-density lipoprotein cholesterol (-32%), while increasing HDL- cholesterol (+27%), representing a promising therapy for multiple lipid disorders. Human C19orf80 genome location and C19orf80 gene details page in the UCSC Genome Browser.
In biochemistry, control coefficients are used to describe how much influence a given reaction step has on the flux or concentration of the species at steady state. This can be accomplished experimentally by changing the expression level of a given enzyme and measuring the resulting changes in flux and metabolite levels. In theory, any observables, such as growth rate, or even combinations of observables, can be defined using a control coefficient; but flux and concentration control coefficients are by far the most commonly used. The simplest way to look at control coefficients is as the scaled derivatives of the steady-state change in an observable with respect to a change in enzyme activity (ei for each species i). For example, the flux control coefficients (C Jei, where J is the reaction rate) can be written as: C e i J = d J d e i e i J = d ln J d ln e i ≈ J % e i % {\displaystyle C_{e_{i}}^{J}={\frac {dJ}{de_{i}}}{\frac {e_{i}}{J}}={\frac {d\ln J}{d\ln e_{i}}}\approx {\frac {J\%}{e_{i}\%}}}
Sources: en.wikipedia.org
== History == The company was founded by Jerry Cole and John Parmer in 1955 and took up shop in a 1,200-square-foot (110 m2) loft on West Illinois Street in downtown Chicago. In the 1960s, Cole-Parmer acquired Masterflex peristaltic pumps, followed shortly by the purchases of Gilmont Instruments and Manostat Pumps. They were acquired by Fisher Scientific, now Thermo-Fisher Scientific, in 2001. On July 17, 2014, Thermo Fisher Scientific Inc. agreed to sell one of its lab units, Cole-Parmer, to private-equity firm GTCR for $480 million in cash. The company has previously said its $13.6 billion acquisition of Life Technologies Corp. would allow it to cut costs while gaining from next-generation genetic-sequencing machines. It has also sought to expand in Asia-Pacific markets. In 2025, Cole-Parmer was sold to Brookfield Asset Management Ltd.'s private equity group and Caisse de dépôt et placement du Québec for a reported 1.4 billion dollars (USD).
In 2003, Burger King hired the Miami-based advertising agency Crispin Porter + Bogusky (CP+B), which completely reorganized its advertising with a series of new campaigns. CP+B was known for having a hip, subversive tack when creating campaigns for its clients, exactly what BK was looking for. Their strategy centered on a redesigned Burger King character used during the 1970s/1980s Burger King Kingdom children's advertising campaign as a caricatured variation, now simply called "the King". While highly successful, some of CP+B's commercials were derided for perceived sexism or cultural insensitivity. Burger King's new owner, 3G Capital, later terminated the relationship with CP+B in 2011 and moved its advertising to McGarryBowen to begin a new product-oriented campaign with expanded demographic targeting. Additionally, CP+B created a series of new characters like the Subservient Chicken and the faux nu-metal band Coq Roq, featured in a series of viral web-based advertisements on sites such as MySpace and various Burger King corporate pages, to complement various television and print promotional campaigns. One of the more successful promotions that CP+B devised was the creation of a series of three advergames for the Xbox 360. Created by UK-based Blitz Games and featuring company celebrity spokesman Brooke Burke, the games sold more than 3.2 million copies, placing them as one of the top selling games along with another Xbox 360 hit, Gears of War.
=== Scales for fibromyalgia severity === The Fibromyalgia Impact Questionnaire (FIQ) was introduced in 1991 and the Revised Fibromyalgia Impact Questionnaire (FIQR) in 2009. It is used as a way of measuring the impact of fibromyalgia on living, although there is some debate on ratings scales. The polysymptomatic distress scale (PSD) was derived from the 2010 ACR diagnosis criteria and aimed to measure FM severity.
Sources: en.wikipedia.org
Under intense heat, the electrons in the metal ions or small molecules can be excited. These electrons later return to lower energy states, and release light with a colour spectrum characteristic of the species present. In chemical synthesis, salts are often used as precursors for high-temperature solid-state synthesis. Many metals are geologically most abundant as salts within ores. To obtain the elemental materials, these ores are processed by smelting or electrolysis, in which redox reactions occur (often with a reducing agent such as carbon) such that the metal ions gain electrons to become neutral atoms.
While de jure not part of West Germany, for Berlin was under the control of the Allied Control Council, West Berlin politically aligned itself with West Germany and was directly or indirectly represented in its federal institutions. The foundation for the influential position held by Germany today was laid during the economic miracle of the 1950s (Wirtschaftswunder), when West Germany rose from the enormous destruction wrought by World War II to become the world's second-largest economy. The first Chancellor Konrad Adenauer, who remained in office until 1963, worked for a full alignment with the NATO rather than neutrality, and secured membership in the military alliance. Adenauer was also a proponent of agreements that developed into the present-day European Union. When the G6 was established in 1975, there was no serious debate as to whether West Germany would become a member. Following the collapse of the Eastern Bloc, symbolised by the opening of the Berlin Wall, both states took action to achieve German reunification. East Germany voted to dissolve and accede to the Federal Republic of Germany in 1990. The five post-war states (Länder) were reconstituted, along with the reunited Berlin, which ended its special status and formed a sixth Land. They formally joined the federal republic on 3 October 1990, raising the total number of states from ten to 16, and ending the division of Germany.
=== Industrial uses === The iron compounds produced on the largest scale in industry are iron(II) sulfate (FeSO4·7H2O) and iron(III) chloride (FeCl3). The former is one of the most readily available sources of iron(II), but is less stable to aerial oxidation than Mohr's salt ((NH4)2Fe(SO4)2·6H2O). Iron(II) compounds tend to be oxidized to iron(III) compounds in the air.
== Research == Wu's research has focused on cardiac biomarkers, clinical toxicology, point-of-care diagnostics, and pharmacogenomics. He has published over 550 peer-reviewed papers and co-authored multiple book chapters and clinical textbooks. In the area of cardiac markers, he and his research group were among the first to evaluate the clinical value of cardiac troponin and the natriuretic peptides that are in widespread clinical use today. He has been active on committees to standardize testing and has participated in the creation and authorship of clinical practice guidelines for cardiac markers. More recently, he has conducted research on biomarkers for traumatic brain injury and contributed a textbook on this topic. His group was among the first clinical labs to initiate untargeted identifications using exact molecular formula. During the COVID-19 pandemic, Wu suspended his normal research work to conduct laboratory-based studies on SARS-CoV-2 molecular, antigen and antibody testing. In addition to his scientific publications, Wu is the author of eight books of short stories designed to raise public awareness of laboratory medicine. His stories are based on real cases, where the and aim to depict the behind-the-scenes role of lab professionals in patient care. He has also launched a social media campaign to educate the general public as to the value of the clinical laboratory. His advocacy stresses that clinical labs are essential in both diagnosis and long-term health management, especially in emergency settings and public health crises.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.